论文部分内容阅读
目的研究检测三种肿瘤标志物对乳腺癌的临床价值。方法择取本院2011年1月-2012年12月间确诊为乳腺癌病患、良性乳腺肿瘤病患以及健康体检人群中各90名作为研究对象,对上述对象血清中CEA、CA125、CA15-3水平进行检测;并将90例乳腺癌患者参照临床最新分期标准划分为3个等级,分析比较每组各项指标的实验数据,分别计算联合检测及各项指标的阳性率。结果乳腺癌组CEA、CA125、CA15-3的阳性率分别是16.9%、32.1%、45%,联合检测的阳性率是75.8%,均高于健康对照组和良性乳腺肿瘤组,差异有统计学意义。就CEA、CA125、CA15-3的水平:乳腺癌组>良性乳腺肿瘤组>健康对照组,差异有统计学意义。乳腺癌组患者CEA、CA125及CA15-3水平:Ⅳ期>Ⅲ期>Ⅰ-Ⅱ期。差异有统计学意义。结论联合检测CEA、CA125、CA15-3对乳腺癌的治疗具有临床诊断价值。
Objective To study the clinical value of detecting three kinds of tumor markers in breast cancer. Methods 90 patients diagnosed as breast cancer, benign breast tumor and healthy physical examination in our hospital from January 2011 to December 2012 were selected as research objects. The serum levels of CEA, CA125, CA15- 3 levels were detected. 90 cases of breast cancer patients were divided into three grades according to the latest clinical staging criteria. The experimental data of each index were analyzed and compared, and the positive rates of the combined tests and the indexes were calculated respectively. Results The positive rates of CEA, CA125 and CA15-3 in breast cancer group were 16.9%, 32.1% and 45%, respectively. The positive rate of combined detection was 75.8%, which were higher than that of healthy control group and benign breast tumor group significance. The level of CEA, CA125, CA15-3: breast cancer group> benign breast tumor group> healthy control group, the difference was statistically significant. The levels of CEA, CA125 and CA15-3 in patients with breast cancer: stage Ⅳ> stage Ⅲ> stage Ⅰ-Ⅱ. The difference was statistically significant. Conclusion The combined detection of CEA, CA125 and CA15-3 has clinical value in the treatment of breast cancer.